LIPOSYN III 20%
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LIPOSYN III 20% (LIPOSYN III 20%).
Liposyn III 20% is a lipid emulsion providing essential fatty acids (linoleic and linolenic acids) and calories. It serves as a source of energy and prevents essential fatty acid deficiency by supplying triglycerides that are hydrolyzed to free fatty acids and glycerol for metabolism.
| Metabolism | Hydrolyzed by lipoprotein lipase to free fatty acids and glycerol; further metabolized via beta-oxidation and the Krebs cycle. Non-oxidative pathways include re-esterification and storage in adipose tissue. |
| Excretion | Primarily eliminated via endogenous lipid metabolic pathways (beta-oxidation in tissues). <5% excreted unchanged in urine; minimal biliary/fecal elimination. |
| Half-life | The terminal elimination half-life of infused triglycerides is approximately 0.5–1 h (33–60 min). Clearance is saturable; at high infusion rates, half-life may prolong. |
| Protein binding | Triglycerides are carried in chylomicrons and VLDL; not significantly bound to plasma proteins. Free fatty acids released by lipolysis are >99% bound to albumin. |
| Volume of Distribution | Vd is approximately 0.1 L/kg, reflecting distribution primarily within plasma compartment. This small Vd indicates limited extravascular penetration. |
| Bioavailability | Intravenous: 100% (only route of administration). Oral bioavailability is negligible due to gastrointestinal digestion; not administered orally. |
| Onset of Action | Intravenous infusion: Immediate increase in plasma triglyceride and free fatty acid levels, with metabolic effects (e.g., energy supply) starting within minutes. |
| Duration of Action | Duration of caloric effect persists as long as infusion continues. After discontinuation, plasma triglycerides return to baseline within 72 h in adults with normal lipid metabolism. |
Adults: 500 mL to 2500 mL per day via continuous intravenous infusion (including peripheral or central vein); typical rate: 0.5-1 mL/kg/h initially, increasing to 1.5-2 mL/kg/h as tolerated. Maximum infusion rate: 2.5 mL/kg/h.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment required for renal impairment. Use with caution in patients with severe renal failure (eGFR <30 mL/min/1.73m²) due to potential fluid and electrolyte imbalances. |
| Liver impairment | Contraindicated in severe hepatic insufficiency (Child-Pugh class C). In moderate impairment (Child-Pugh class B), reduce dose by 50% and monitor triglycerides and liver function closely. |
| Pediatric use | Neonates and infants: 0.5-1 g fat/kg/day (2.5-5 mL/kg/day) initially, increase by 0.5 g fat/kg/day to maximum of 3 g fat/kg/day (15 mL/kg/day). Children: 1-2 g fat/kg/day (5-10 mL/kg/day) up to 3 g fat/kg/day. Administer via continuous infusion over 24 hours. |
| Geriatric use | Initiate at low end of adult dosing (500 mL/day) and titrate slowly; monitor for fluid overload, hypertriglyceridemia, and electrolyte disturbances due to reduced cardiovascular and renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LIPOSYN III 20% (LIPOSYN III 20%).
| Breastfeeding | Liposyn III 20% is a fat emulsion; lipids are normal constituents of breast milk. The M/P ratio is not determined, but intravenous administration of lipids is unlikely to significantly alter breast milk composition; however, use during lactation only if clearly needed. Caution: high doses may affect milk fat content. |
| Teratogenic Risk | Liposyn III 20% (intravenous lipid emulsion) is not known to be teratogenic. Animal reproduction studies have not been conducted; however, as a source of essential fatty acids and calories, it is used when indicated during pregnancy. There are no well-controlled studies in pregnant women. First trimester: limited data, theoretical risk only if underlying maternal condition is poorly managed. Second and third trimesters: considered safe when clinically necessary; risk of preterm labor or fetal distress not directly attributed to the drug itself but to underlying maternal nutritional deficiency. |
■ FDA Black Box Warning
Death in preterm infants: Premature infants, especially those with respiratory distress syndrome, have developed severe lipid accumulation in the lungs (pulmonary lipid deposits) and fatal pulmonary complications. Parenteral nutrition with lipid emulsions should be used with caution in preterm infants.
| Serious Effects |
["Hypersensitivity to eggs, soybeans, peanuts, or any component","Severe hyperlipidemia (including pathologic hyperlipemia)","Lipoid nephrosis","Acute pancreatitis with hypertriglyceridemia","Severe hepatic insufficiency"]
| Precautions | ["Risk of fat overload syndrome (hypertriglyceridemia, hepatomegaly, coagulopathy, respiratory distress)","Monitor serum triglycerides; discontinue if severely elevated","Use with caution in patients with hepatic or renal impairment","Risk of infections due to contamination (single-use only)","Avoid in patients with severe hyperlipidemia or lipid metabolism disorders","May cause allergic reactions (soybean oil or egg phospholipid allergy)"] |
| Food/Dietary | No direct food interactions as Liposyn III is administered intravenously. However, dietary fat intake should be managed if oral/enteral nutrition is also given, to avoid excessive total fat intake. Monitor for interactions with oral anticoagulants due to vitamin K content in some lipid emulsions; Liposyn III contains soybean oil, which has vitamin K1. |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum triglycerides, liver function tests, and platelet count regularly to avoid fat overload syndrome. Monitor fetal growth and well-being with ultrasound if used long-term. Watch for signs of maternal hypertriglyceridemia (e.g., pancreatitis). |
| Fertility Effects | No known adverse effects on fertility. Adequate nutrition supports normal reproductive function. |
| Clinical Pearls | Liposyn III 20% is a lipid emulsion used for parenteral nutrition. Monitor triglycerides regularly; hold if >400 mg/dL in adults or >200 mg/dL in pediatrics. Use inline filter with 1.2-micron pore size. Do not administer with other IV lines unless compatible. Check for signs of fat overload syndrome (hepatosplenomegaly, coagulopathy, hyperlipidemia). In neonates, limit to 3 g/kg/day to prevent hypertriglyceridemia and risk of pulmonary emboli. |
| Patient Advice | This medication is a fat emulsion that provides calories and essential fatty acids through your IV. · Report any signs of allergic reaction: rash, itching, difficulty breathing, or swelling. · You will have regular blood tests to check your triglyceride levels. · Tell your healthcare provider if you have diabetes, pancreatitis, or liver disease. · Do not stop or change the infusion rate without consulting your care team. |